Luke Halpern, Assistant Editor from Pharmacy Times - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Luke Halpern, Assistant Editor Pharmacy Times		FDA Approves Biosimilar Denosumab-dssb to Treat Osteoporosis-, Cancer-Related Bone Loss - 6 days ago Video: Etranacogene Dezaparvovec Has Long-Term Efficacy, Can Expand Eligibility for Hemophilia B - 6 days ago FDA Grants Fast Track Designation to Amlenetug for Possible Treatment of Multiple System Atrophy - 7 days ago Etranacogene Dezaparvovec-drlb Delivers Sustained, Increased Bleed Protection Compared With Prophylaxis in Hemophilia B - 8 days ago Potential Drug for Mitigation of Cannabis Withdrawal Symptoms Receives FDA Fast Track Designation - 8 days ago As Nonopioid Alternatives for Pain Management Emerge, Pharmacists Prove Essential - 9 days ago FDA Grants Fast Track Designation to Amezalpat for Treatment of Hepatocellular Carcinoma - 10 days ago FDA Accepts BLA for Lerodalcibep, a Novel Agent to Lower LDL-Cholesterol in Atherosclerotic Cardiovascular Disease - 10 days ago Patients With Cytopenic Primary Myelofibrosis Face Unique Therapeutic Challenges, Poor Prognosis - 11 days ago FDA Approves Mirdametinib for Treatment of Adults, Children With NF1-PN - 11 days ago SARS-CoV-2 Infection Associated With Increased Plaque in Coronary Arteries, Higher Risk of Cardiac Events - 12 days ago IVIG Does Not Reduce Late Gadolinium Enhancement Burden in Pediatrics With Myocarditis - 17 days ago Young Adults With Sickle Cell Disease Have Elevated p16 mRNA, Contributing to Premature Aging - 17 days ago Expert: Abelacimab Shows Significant Bleeding Reduction, Offering Safer Option for Atrial Fibrillation Treatment - 18 days ago Study: Mechanisms Impacting LDL-C Are Inversely Associated With Type 2 Diabetes Risk - 18 days ago IVIG Prophylaxis Significantly Reduces Hospital Admissions for Fever in Pediatrics With ALL - about 1 month ago Key Drugs to Watch in Oncology, Hematology, and Neurology for 2025 - about 1 month ago FDA Approves Acalabrutinib With Bendamustine, Rituximab For Patients With Previously Untreated Mantle Cell Lymphoma - about 1 month ago COVID-19 Infection Associated With Higher Likelihood of Developing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - about 1 month ago Transfusing More Blood to Heart Attack Patients With Anemia Reduces Risk of Death - about 2 months ago Fear of COVID-19 Among Post-Infected Adults Can Impact Quality of Life - about 2 months ago Relacorilant NDA Submitted to FDA for Treatment of Endogenous Hypercortisolism - about 2 months ago Intravenous Immunoglobulin Shows Efficacy as Adjunctive Therapy for Treatment of Pyoderma Gangrenosum - about 2 months ago Anemia in Patients With Cancer Causes Significant Fatigue, Impacting Quality of Life - about 2 months ago Majority of Children, Young Patients With Long COVID Recover Within 2 Years - about 2 months ago MRX-5 Receives FDA Orphan Drug Designation for Treatment of Non-Tuberculous Mycobacteria Infections - about 2 months ago ASH 2024: Zanubrutinib Monotherapy, With Obinutuzimab Demonstrates Durable Efficacy and Safety in CLL/SLL - about 2 months ago Updated BNT162b2 XBB COVID-19 Vaccine Protects Against Hospitalization in Children Aged 5 to 17 - about 2 months ago ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma - about 2 months ago Dupilumab Lowers Incidence of Psychiatric and Sleep Disorders in Patients With Atopic Dermatitis - 2 months ago Mild IVIG-Related Adverse Events Are Frequent in Children, With Serious Reactions Possible - 2 months ago FDA Approves Vibegron for Men With Overactive Bladder Symptoms Receiving Therapy for Benign Prostatic Hyperplasia - 2 months ago FDA Approves First Generic of Liraglutide Injection to Lower Blood Sugar in Patients With Type 2 Diabetes - 2 months ago ASH 2024: Nuvisertib Demonstrates Durable Response in Relapsed/Refractory Myelofibrosis - 2 months ago Sacituzumab Govitecan-hziy Receives FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer Treatment - 2 months ago IVIG Identified as a Treatment Marker of High Medical Costs, Resource Utilization in Patients With Myasthenia Gravis - 2 months ago FDA Grants Breakthrough Therapy Designation to Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis - 2 months ago ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma - 2 months ago ASH 2024: Rapid Uptake of Bispecific Antibodies for R/R Multiple Myeloma Observed in Community Oncology Settings - 3 months ago ASH 2024: New Treatments in Trial Pipeline Show Promising Survival Rates in R/R Multiple Myeloma - 3 months ago ASH: Zanubrutinib Demonstrates Long-Term Efficacy in Patients With Waldenström Macroglobulinemia - 3 months ago ASH 2024: Pharmacists Play Key Role in Incorporating Venetoclax, Blinatumomab for Treatment of Hematologic Malignancies - 3 months ago ASH: Cilta-Cel Significantly Increases Minimum Residual Disease Negativity in Lenalidomide-Refractory Multiple Myeloma - 3 months ago ASH Expert: Axi-Cel Treatment Causes Decreased Incidence, Severity of Toxicities in Large B-Cell Lymphoma - 3 months ago ASH 2024: Bispecific Antibodies Face Key Challenges for Implementation in Community Cancer Centers - 3 months ago ASH 2024: Leukemia Biology Can Predict Patterns of Blinatumomab Failure in Patients with B-Cell ALL - 3 months ago ASH 2024: Expert Highlights Zanubrutinib's Sustained Efficacy, Favorable Safety Profile in CLL - 3 months ago Make Vaccination Easy: Jerome Adams' Call to Health Care Workers This Flu, COVID-19 Season - 3 months ago NABP Executive Director Encourages Self-Care, Proper Work-Life Balance Among Burnt-Out Pharmacy Workforce - 3 months ago High-Dose IVIG, Rituximab Effective in Patients With Pemphigoid-Associated Conjunctivitis - 3 months ago